Zevra Therapeutics, Inc.

Total Valuation

Zevra Therapeutics, Inc. carries a market capitalization of 735.98M, placing it among publicly traded companies globally. Its enterprise value stands at 325.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Zevra Therapeutics, Inc. currently has 59.11M shares outstanding.

Valuation Ratios

Zevra Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 4.23. The price-to-sales ratio is 4.30, and the price-to-book ratio stands at -1.37.

Enterprise Valuation

On an enterprise value basis, Zevra Therapeutics, Inc. trades at an EV/EBITDA multiple of 25.60 and an EV/FCF ratio of 15.73. The EV/Sales ratio of 2.67 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 32.73 provides insight into valuation relative to core operating earnings.

Financial Position

Zevra Therapeutics, Inc. maintains a current ratio of 4.89, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.56, indicating moderate leverage, while an interest coverage ratio of 1.65 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Zevra Therapeutics, Inc. has paid 9.18M in income taxes, reflecting an effective tax rate of 6.88.

Stock Price Statistics

Zevra Therapeutics, Inc.'s stock has gained approximately 6.13811% over the past 52 weeks. The 50-day moving average sits at 12.26, while the 200-day moving average is 10.10.

Income Statement

Over the trailing twelve months, Zevra Therapeutics, Inc. generated 122.29M in revenue and converted that into 124.22M in net income, yielding earnings per share of 2.16. EBITDA reached 12.73M, while operating income came in at 9.96M.

Balance Sheet

Zevra Therapeutics, Inc. holds 200.62M in cash and equivalents against 1.15M in total debt, resulting in a net debt position of -95.59M. Total book value stands at -384.16M, with working capital of 182.94M providing operational flexibility.

Cash Flow

Zevra Therapeutics, Inc. produced 12.77M in operating cash flow over the past twelve months. After subtracting -771,000.00 in capital expenditures, free cash flow totaled 12.00M - equivalent to 0.21 per share.

Margins

Zevra Therapeutics, Inc. operates with a gross margin of 86.07, reflecting its pricing power and cost economics. The operating margin of 8.15 and net profit margin of 101.58 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Zevra Therapeutics, Inc.'s most recent stock split took place on December 28, 2020 with a 16:1 split ratio.

Scores

Zevra Therapeutics, Inc. posts an Altman Z-Score of 3.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.